加载中
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
常规交易时段
US$26.9101
−US$0.8099 · -2.92%
盘中时间采用ET。市场数据可能有所延迟。
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
日内区间
当前US$26.9101
52周区间
当前US$26.9101
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
33
偏贵
情绪
53
多空交织
风险
50
风险偏高
动量
73
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
日内区间
当前US$26.9101
52周区间
当前US$26.9101
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$80.89
上涨空间 200.59%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6610.85万0.00%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI5396.6万0.55%103.03亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM4542.52万0.06%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF2615.15万0.03%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO1636.13万0.12%139.17亿 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB1263.2万0.12%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO1251.56万0.07%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA905.5万0.04%217.13亿 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
